# Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Inc. is an other based in Pittsburgh, United States.

## Overview

- **Organization type:** other
- **Headquarters:** Pittsburgh, United States
- **Region:** North America
- **Address:** Pittsburgh, PA, United States
- **Assets under management:** Undisclosed
- **Website:** lipellapharmaceuticals.com

## Regulatory record

- **Reports private funds:** No

## About

Lipella Pharmaceuticals was taken public through a reverse merger in 2021, with Jonathan Kaufman serving as CEO. The company operates as a developmental-stage biotech, not a family office or asset manager; its primary business is drug development rather than capital management. The firm's strategy centers on drug reformulation — taking existing FDA-approved compounds and testing them for new therapeutic uses. Its lead candidate, LP-10, targets hemorrhagic cystitis, a condition often caused by chemotherapy. Additional pipeline assets focus on oral mucositis and other inflammatory disorders. Lipella's geographic footprint is US-based, with operations centered in Pittsburgh. Lipella is a publicly traded entity on the OTC markets under the ticker LIPO. The company's team size and institutional capital commitments are not publicly detailed. The firm has disclosed clinical trial data through press releases and regulatory filings, but no funded deployment figures are available. A structural differentiator is Lipella's use of the 505(b)(2) regulatory pathway, which leverages existing safety data to reduce development cost and time. This framework shapes the firm's risk profile and capital requirements, setting it apart from traditional biotechs that start from novel compounds.

## Sectors

- Healthcare Services

## People

- Jonathan H. Kaufman — Chief Executive Officer

## Questions

### How is Lipella Pharmaceuticals structured?

Lipella is a publicly traded company, not a family office or investment vehicle. It files financial statements with the SEC and trades under the ticker LIPO on the OTC markets. Its primary business is drug development, not capital management.

### What is Lipella's therapeutic focus?

Lipella targets localized diseases in urology and oncology, particularly conditions affecting the bladder and oral mucosa. Its lead program addresses hemorrhagic cystitis, a chemotherapy side effect.

### What regulatory strategy does Lipella use?

Lipella employs the 505(b)(2) regulatory pathway, which allows it to reference existing safety data from previously approved drugs. This approach reduces clinical development costs and accelerates time to market for new indications.

### Who runs Lipella Pharmaceuticals?

Jonathan H. Kaufman serves as Chief Executive Officer. The company's leadership team is disclosed in SEC filings, but additional professional names are not part of the public record at this time.

### Does Lipella Pharmaceuticals provide investor updates?

Yes. As a public company, Lipella discloses material developments through press releases, SEC filings, and periodic conference calls. The firm has shared clinical trial results and pipeline updates via these channels.

## Related profiles

- [1606 Corp.](https://altss.com/profile/1606-corp)
- [Cloudweb](https://altss.com/profile/cloudweb-inc)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/lipella-pharmaceuticals-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology